1.The efficacy of SPA0355 in protecting beta cells in isolated pancreatic islets and in a murine experimental model of type 1 diabetes.
Ui Jin BAE ; Mi Young SONG ; Hyun Young JANG ; Hyo Jin GIM ; Jae Ha RYU ; Sang Myeong LEE ; Raok JEON ; Byung Hyun PARK
Experimental & Molecular Medicine 2013;45(11):e51-
Cytokines activate several inflammatory signals that mediate beta-cell destruction. We recently determined that SPA0355 is a strong anti-inflammatory compound, thus reporting its efficacy in protecting beta cells from various insults. The effects of SPA0355 on beta-cell survival were studied in RINm5F cells and primary islets. The protective effects of this compound on the development of type 1 diabetes were evaluated in non-obese diabetic (NOD) mice. SPA0355 completely prevented cytokine-induced nitric oxide synthase (iNOS) expression and cytotoxicity in RINm5F cells and isolated islets. The molecular mechanism of SPA0355 inhibition of iNOS expression involves the inhibition of nuclear factor kappaB and Janus kinase signal transducer and activator of transcription pathways. The protective effects of SPA0355 against cytokine toxicity were further demonstrated by normal insulin secretion and absence of apoptosis of cytokine-treated islets. In experiments with NOD mice, the occurrence of diabetes was efficiently reduced when the mice were treated with SPA0355. Therefore, SPA0355 might be a valuable treatment option that delays the destruction of pancreatic beta cells in type 1 diabetes.
Animals
;
Apoptosis
;
Benzoxazines/pharmacology/*therapeutic use
;
Cell Line
;
Cell Survival
;
Cells, Cultured
;
Diabetes Mellitus, Experimental/*prevention & control
;
Insulin-Secreting Cells/*drug effects/metabolism
;
Janus Kinases/genetics/metabolism
;
Mice
;
Mice, Inbred NOD
;
NF-kappa B/genetics/metabolism
;
Nitric Oxide Synthase Type II/genetics/metabolism
;
Rats
;
Thiourea/*analogs & derivatives/pharmacology/therapeutic use
2.Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
Lawrence S U LEE ; Paul PHAM ; Charles FLEXNER
Annals of the Academy of Medicine, Singapore 2012;41(12):559-562
INTRODUCTIONEfavirenz is an inducer of drug metabolism enzymes. We studied the effect of efavirenz and ritonavir-boosted darunavir on serum unconjugated and conjugated bilirubin, as probes for UGT1A1 and bile transporters.
MATERIALS AND METHODSHealthy volunteers were enrolled in a clinical trial. There were 3 periods: Period 1, 10 days of darunavir 900 mg with ritonavir 100 mg once daily; Period 2, 14 days of efavirenz 600 mg with darunavir/ritonavir once daily; and Period 3, 14 days of efavirenz 600 mg once daily. Serum bilirubin (conjugated and unconjugated) concentrations were obtained at baseline, at the end of each phase and at exit.
RESULTSWe recruited 7 males and 5 females. One subject developed grade 3 hepatitis on efavirenz and was excluded. Mean serum unconjugated bilirubin concentrations were 6.09 μmol/L (95% confidence interval [CI], 4.99 to 7.19) at baseline, 5.82 (95% CI, 4.88 to 6.76) after darunavir/ritonavir, 4.00 (95% CI, 2.92 to 5.08) after darunavir/ritonavir with efavirenz, 3.55 (95% CI, 2.58 to 4.51) after efavirenz alone and 5.27 (95% CI, 3.10 to 7.44) at exit (P <0.01 for the efavirenz phases). Mean serum conjugated bilirubin concentrations were 3.55 μmol/L (95% CI, 2.73 to 4.36) at baseline, 3.73 (95% CI, 2.77 to 4.68) after darunavir/ritonavir, 2.91 (95% CI, 2.04 to 3.78) after darunavir/ritonavir with efavirenz, 2.64 (95% CI, 1.95 to 3.33) after efavirenz alone and 3.55 (95% CI, 2.19 to 4.90) at exit (P <0.05 for the efavirenz phases).
CONCLUSIONEfavirenz decreased unconjugated bilirubin by 42%, suggesting UGT1A1 induction. Efavirenz also decreased conjugated bilirubin by 26%, suggesting induction of bile efflux transporters. Ritonavir-boosted darunavir had no effect on bilirubin concentrations. These results indicate that efavirenz may reduce concentrations of drugs or endogenous substances metabolized by UGT1A1 or excreted by bile efflux transporters.
Adult ; Aged ; Anti-HIV Agents ; therapeutic use ; Benzoxazines ; pharmacology ; Biological Transport ; Confidence Intervals ; Darunavir ; Dose-Response Relationship, Drug ; Drug Interactions ; Enzyme Induction ; drug effects ; Female ; Glucuronosyltransferase ; biosynthesis ; blood ; HIV Infections ; drug therapy ; HIV Protease Inhibitors ; Humans ; Incidental Findings ; Male ; Membrane Transport Proteins ; drug effects ; metabolism ; Middle Aged ; Ritonavir ; pharmacology ; Sulfonamides ; pharmacology ; Young Adult
3.Spinal CCL2 Promotes Central Sensitization, Long-Term Potentiation, and Inflammatory Pain via CCR2: Further Insights into Molecular, Synaptic, and Cellular Mechanisms.
Rou-Gang XIE ; Yong-Jing GAO ; Chul-Kyu PARK ; Ning LU ; Ceng LUO ; Wen-Ting WANG ; Sheng-Xi WU ; Ru-Rong JI
Neuroscience Bulletin 2018;34(1):13-21
Mounting evidence supports an important role of chemokines, produced by spinal cord astrocytes, in promoting central sensitization and chronic pain. In particular, CCL2 (C-C motif chemokine ligand 2) has been shown to enhance N-methyl-D-aspartate (NMDA)-induced currents in spinal outer lamina II (IIo) neurons. However, the exact molecular, synaptic, and cellular mechanisms by which CCL2 modulates central sensitization are still unclear. We found that spinal injection of the CCR2 antagonist RS504393 attenuated CCL2- and inflammation-induced hyperalgesia. Single-cell RT-PCR revealed CCR2 expression in excitatory vesicular glutamate transporter subtype 2-positive (VGLUT2) neurons. CCL2 increased NMDA-induced currents in CCR2/VGLUT2 neurons in lamina IIo; it also enhanced the synaptic NMDA currents evoked by dorsal root stimulation; and furthermore, it increased the total and synaptic NMDA currents in somatostatin-expressing excitatory neurons. Finally, intrathecal RS504393 reversed the long-term potentiation evoked in the spinal cord by C-fiber stimulation. Our findings suggest that CCL2 directly modulates synaptic plasticity in CCR2-expressing excitatory neurons in spinal lamina IIo, and this underlies the generation of central sensitization in pathological pain.
Animals
;
Benzoxazines
;
pharmacology
;
therapeutic use
;
Chemokine CCL2
;
antagonists & inhibitors
;
genetics
;
metabolism
;
pharmacology
;
Excitatory Amino Acid Agents
;
pharmacology
;
Excitatory Amino Acid Agonists
;
pharmacology
;
Female
;
Freund's Adjuvant
;
toxicity
;
Hyperalgesia
;
chemically induced
;
metabolism
;
prevention & control
;
Long-Term Potentiation
;
drug effects
;
physiology
;
Luminescent Proteins
;
genetics
;
metabolism
;
Male
;
Mice
;
Mice, Inbred C57BL
;
Mice, Transgenic
;
Myelitis
;
chemically induced
;
drug therapy
;
metabolism
;
Neurons
;
drug effects
;
Pain Management
;
Somatostatin
;
genetics
;
metabolism
;
Spinal Cord
;
cytology
;
Spiro Compounds
;
pharmacology
;
therapeutic use
;
Vesicular Glutamate Transport Protein 2
;
genetics
;
metabolism
;
Vesicular Inhibitory Amino Acid Transport Proteins
;
genetics
;
metabolism